Avalo Therapeutics Announces First Patient Dosed in the Phase II PEAK Trial of AVTX-002 for the Treatment of Non-Eosinophilic Asthma (NEA)

Avalo Therapeutics, Inc. announced that the first patient has been dosed in the company’s Phase II PEAK trial evaluating AVTX-002 for the treatment of NEA.